{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:42:23Z","timestamp":1790937743631,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1-R01-HL079184"],"award-info":[{"award-number":["1-R01-HL079184"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-93773"],"award-info":[{"award-number":["MOP-93773"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.biomaterials.2010.03.074","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T09:03:01Z","timestamp":1272445381000},"page":"5741-5748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro"],"prefix":"10.1016","volume":"31","author":[{"given":"Albert","family":"Adam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Montpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Keire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"D\u00e9sormeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Marceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Westenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biomaterials.2010.03.074_bib1","first-page":"124","article-title":"Acute allergic-type reactions among patients undergoing hemodialysis\u2013multiple states, 2007\u20132008","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nbt0608-621","article-title":"The FDA and safety\u2013beyond the heparin crisis","volume":"26","author":"Laurencin","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biomaterials.2010.03.074_bib3","author":"U.S. Department of Health & Human Services"},{"issue":"5","key":"10.1016\/j.biomaterials.2010.03.074_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/ki.1990.301","article-title":"Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors","volume":"38","author":"Tielemans","year":"1990","journal-title":"Kidney Int"},{"issue":"8727","key":"10.1016\/j.biomaterials.2010.03.074_bib5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0140-6736(90)92904-V","article-title":"Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis","volume":"336","author":"Verresen","year":"1990","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2010.03.074_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0008-6215(97)10060-X","article-title":"Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation","volume":"306","author":"Maruyama","year":"1998","journal-title":"Carbohydr Res"},{"issue":"23","key":"10.1016\/j.biomaterials.2010.03.074_bib8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","article-title":"Contaminated heparin associated with adverse clinical events and activation of the contact system","volume":"358","author":"Kishimoto","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/1076029608324291","article-title":"Contaminated heparin preparations, severe adverse events and the contact system","volume":"14","author":"Ramacciotti","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.biomaterials.2010.03.074_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1987.tb33047.x","article-title":"The activation of the contact system of human plasma by polysaccharide sulfates","volume":"516","author":"Silverberg","year":"1987","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.V59.6.1225.1225","article-title":"The contact activation mechanism in human plasma: activation induced by dextran sulfate","volume":"59","author":"van der Graaf","year":"1982","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biomaterials.2010.03.074_bib12","doi-asserted-by":"crossref","first-page":"H275","DOI":"10.1152\/ajpheart.2001.281.1.H275","article-title":"Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma","volume":"281","author":"Cyr","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"10.1016\/j.biomaterials.2010.03.074_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.biomaterials.2007.11.019","article-title":"The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes","volume":"29","author":"Desormeaux","year":"2008","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1523-1755.1998.00837.x","article-title":"Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin","volume":"53","author":"Krieter","year":"1998","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jpba.2009.10.017","article-title":"Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate","volume":"51","author":"Keire","year":"2010","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.biomaterials.2010.03.074_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpba.2008.12.013","article-title":"Analysis of heparin sodium by SAX\/HPLC for contaminants and impurities","volume":"49","author":"Trehy","year":"2009","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.biomaterials.2010.03.074_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0196-9781(94)90214-3","article-title":"Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues","volume":"15","author":"Decarie","year":"1994","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.biomaterials.2010.03.074_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-1759(94)00320-V","article-title":"Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation","volume":"180","author":"Raymond","year":"1995","journal-title":"J Immunol Methods"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0196-9781(99)00020-0","article-title":"Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P","volume":"20","author":"Blais","year":"1999","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.biomaterials.2010.03.074_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1537-2995.2007.01097.x","article-title":"Generation of kinins during preparation and storage of whole blood-derived platelet concentrates","volume":"47","author":"Moreau","year":"2007","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.biomaterials.2010.03.074_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/jpet.107.123422","volume":"323","author":"Bawolak","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"10.1016\/j.biomaterials.2010.03.074_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0162-3109(99)00128-9","article-title":"Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist","volume":"43","author":"Pruneau","year":"1999","journal-title":"Immunopharmacology"},{"issue":"1","key":"10.1016\/j.biomaterials.2010.03.074_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-3565(24)29506-9","article-title":"Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates","volume":"297","author":"Bachvarov","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biomaterials.2010.03.074_bib24","series-title":"Mathematical statistics and data analysis","author":"Rice","year":"1995"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib25","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood.V72.6.1841.1841","article-title":"Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis","volume":"72","author":"Nuijens","year":"1988","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib26","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.4049\/jimmunol.159.4.1953","article-title":"Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma","volume":"159","author":"Wuillemin","year":"1997","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.biomaterials.2010.03.074_bib27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/clinchem\/31.9.1533","article-title":"Influence of oral contraceptives and pregnancy on constituents of the kallikrein\u2013kininogen system in plasma","volume":"31","author":"Adam","year":"1985","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.biomaterials.2010.03.074_bib28","first-page":"203","article-title":"Optimized determination of plasma prokallikrein on a Hitachi 705 analyser","volume":"23","author":"Adam","year":"1985","journal-title":"J Clin Chem Clin Biochem"},{"issue":"25","key":"10.1016\/j.biomaterials.2010.03.074_bib29","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin","volume":"359","author":"Blossom","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib30","first-page":"1009","article-title":"Effects of captopril and icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema","volume":"17","author":"Decarie","year":"1996","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib31","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/01.STR.0000017284.77838.87","article-title":"Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach","volume":"33","author":"Molinaro","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.biomaterials.2010.03.074_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MBC.0b013e3282f2a9b1","article-title":"Effect of oversulfated chondroitin-6-sulfate or oversulfated fucoidan in the activation of glutamic plasminogen by tissue plasminogen activator: role of lysine and cyanogen bromide-fibrinogen","volume":"19","author":"Carranza","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.biomaterials.2010.03.074_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MBC.0b013e3282f2a99e","article-title":"Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate","volume":"19","author":"Carranza","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1016\/j.biomaterials.2010.03.074_bib34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1523-1755.1999.0550031097.x","article-title":"Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH","volume":"55","author":"Renaux","year":"1999","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.biomaterials.2010.03.074_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"Guidelines on the use and monitoring of heparin","volume":"133","author":"Baglin","year":"2006","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.biomaterials.2010.03.074_bib36","first-page":"1443","volume":"191","author":"Adam","year":"2007","journal-title":"Bull Acad Natl Med"},{"issue":"7","key":"10.1016\/j.biomaterials.2010.03.074_bib37","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjp.0704158","article-title":"Absence of ligand-induced regulation of kinin receptor expression in the rabbit","volume":"133","author":"Sabourin","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.biomaterials.2010.03.074_bib38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961210004588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961210004588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:18:13Z","timestamp":1758899893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961210004588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":38,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0142961210004588"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2010.03.074","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2010.03.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}